Davita (NYSE:DVA) PT Raised to $72.00 at SunTrust Banks

Davita (NYSE:DVA) had its price objective lifted by SunTrust Banks to $72.00 in a research note published on Wednesday morning, The Fly reports. SunTrust Banks currently has a hold rating on the stock. SunTrust Banks also issued estimates for Davita’s Q4 2019 earnings at $1.67 EPS, FY2019 earnings at $5.34 EPS, Q1 2020 earnings at $1.27 EPS, Q2 2020 earnings at $1.42 EPS, Q3 2020 earnings at $1.41 EPS, Q4 2020 earnings at $1.48 EPS and FY2020 earnings at $5.58 EPS.

DVA has been the subject of several other research reports. TheStreet raised Davita from a c+ rating to a b- rating in a research report on Wednesday, July 24th. William Blair lowered Davita from an outperform rating to a market perform rating in a research report on Wednesday, September 11th. Robert W. Baird lowered Davita from an outperform rating to a neutral rating and lowered their price target for the stock from $70.00 to $65.00 in a research report on Friday, July 26th. Wolfe Research lowered Davita from an outperform rating to a market perform rating and set a $57.00 price target for the company. in a research report on Friday, October 25th. Finally, ValuEngine raised Davita from a sell rating to a hold rating in a research report on Wednesday, October 2nd. Nine equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company. The stock presently has a consensus rating of Hold and a consensus price target of $64.81.

Davita stock traded up $0.66 on Wednesday, hitting $69.85. 2,446,213 shares of the stock traded hands, compared to its average volume of 2,127,695. The company has a current ratio of 1.12, a quick ratio of 1.10 and a debt-to-equity ratio of 1.90. The firm has a market cap of $10.01 billion, a P/E ratio of 19.57, a price-to-earnings-growth ratio of 0.62 and a beta of 1.59. The business’s fifty day simple moving average is $58.51 and its 200 day simple moving average is $55.70. Davita has a 1 year low of $43.40 and a 1 year high of $70.51.

Davita (NYSE:DVA) last posted its quarterly earnings results on Tuesday, November 5th. The company reported $1.53 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.24 by $0.29. The firm had revenue of $2.90 billion during the quarter, compared to analyst estimates of $2.85 billion. Davita had a return on equity of 18.03% and a net margin of 3.68%. Davita’s quarterly revenue was up 2.0% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.56 EPS. As a group, analysts predict that Davita will post 5.19 earnings per share for the current year.

A number of large investors have recently modified their holdings of DVA. North Star Investment Management Corp. purchased a new position in shares of Davita during the 3rd quarter valued at $46,000. Rehmann Capital Advisory Group grew its holdings in Davita by 51.3% in the second quarter. Rehmann Capital Advisory Group now owns 841 shares of the company’s stock valued at $47,000 after purchasing an additional 285 shares during the period. Employers Holdings Inc. acquired a new stake in Davita in the second quarter valued at approximately $56,000. NuWave Investment Management LLC grew its holdings in Davita by 1,166.3% in the third quarter. NuWave Investment Management LLC now owns 1,013 shares of the company’s stock valued at $57,000 after purchasing an additional 933 shares during the period. Finally, Neo Ivy Capital Management acquired a new stake in Davita in the second quarter valued at approximately $61,000. 91.00% of the stock is owned by institutional investors and hedge funds.

Davita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure or end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also provides outpatient, hospital inpatient, and home-based hemodialysis services; owns clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.

See Also: What causes a stock to be most active?

The Fly

Analyst Recommendations for Davita (NYSE:DVA)

Receive News & Ratings for Davita Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Davita and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit